Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups.
研究概览
简要总结
Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recently diagnosed essential hypertension (within 6 months).
- •Age 25 to 80 years; Weight < 100kg.
- •Sinus rhythm without significant ventricular or atrial ectopy.
排除标准
- •Current angiotensin II receptor antagonist or ACE Inhibitor treatment.
- •Contra-indication to any of the protocol anti-hypertensive agents.
- •Angina requiring treatment with a Beta blocker or calcium antagonist
- •Any disease affecting the autonomic nervous system e.g. congestive cardiac failure, diabetes, neurological disease, malignancy, pregnancy.
- •Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants, intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes etc).
研究组 & 干预措施
1
Neurohormonal stimulatory arm
干预措施: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD (Drug)
2
Neurohormonal inhibitory arm
干预措施: Valsartan 160mg OD; Moxonidine 400mcg OD (Drug)
结局指标
主要结局
The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups.
时间窗: 6 months
次要结局
未报告次要终点
研究者
Dr JP Greenwood
Senior Lecturer
University of Leeds